Novartis setzt die starke Umsatzdynamik mit Margenerhöhungen fort und erreicht 2024 wichtige Meilensteine bei Innovationen

Novartis setzt die starke Umsatzdynamik mit Margenerhöhungen fort und erreicht 2024 wichtige Meilensteine bei Innovationen
arcticnovartis

Ad-hoc-Mitteilung gemäss Art. 53 KR

Geschäftsjahr

/by
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024

Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

Full year

/by
Novartis presentation at J.P. Morgan Healthcare Conference 2025

Novartis presentation at J.P. Morgan Healthcare Conference 2025
imberje1

/by
Novartis Entresto® US patent upheld by US Court of Appeals

Novartis Entresto® US patent upheld by US Court of Appeals
arcticnovartis

Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto® (sacubitril/valsartan) combination patent.

We will work to appropriately enforce the combination patent through its pediatric exclusivity period expiring in July 2025. We will also continue to defend and protect all our important intellectual property and regulatory rights relating to Entresto.

/by